Selective Modulation of TNF-TNFRs Signaling: Insights for Multiple Sclerosis Treatment

Valentina Pegoretti, Wia Baron, Jon D Laman, Ulrich L M Eisel, Valentina Pegoretti, Wia Baron, Jon D Laman, Ulrich L M Eisel

Abstract

Autoimmunity develops when self-tolerance mechanisms are failing to protect healthy tissue. A sustained reaction to self is generated, which includes the generation of effector cells and molecules that destroy tissues. A way to restore this intrinsic tolerance is through immune modulation that aims at refurbishing this immunologically naïve or unresponsive state, thereby decreasing the aberrant immune reaction taking place. One major cytokine has been shown to play a pivotal role in several autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS): tumor necrosis factor alpha (TNFα) modulates the induction and maintenance of an inflammatory process and it comes in two variants, soluble TNF (solTNF) and transmembrane bound TNF (tmTNF). tmTNF signals via TNFR1 and TNFR2, whereas solTNF signals mainly via TNFR1. TNFR1 is widely expressed and promotes mainly inflammation and apoptosis. Conversely, TNFR2 is restricted mainly to immune and endothelial cells and it is known to activate the pro-survival PI3K-Akt/PKB signaling pathway and to sustain regulatory T cells function. Anti-TNFα therapies are successfully used to treat diseases such as RA, colitis, and psoriasis. However, clinical studies with a non-selective inhibitor of TNFα in MS patients had to be halted due to exacerbation of clinical symptoms. One possible explanation for this failure is the non-selectivity of the treatment, which avoids TNFR2 stimulation and its immune and tissue protective properties. Thus, a receptor-selective modulation of TNFα signal pathways provides a novel therapeutic concept that might lead to new insights in MS pathology with major implications for its effective treatment.

Keywords: TNFR1; TNFR2; immune tolerance; multiple sclerosis; neurodegeneration; tumor necrosis factor alpha.

Figures

Figure 1
Figure 1
Hypothetical working model. TNFα and its receptors regulate major functions of several cell types. This model represents the expected effects of selectively modulating TNF–TNFRs signaling. sTNF, soluble TNF; tmTNF, transmembrane TNF; ATROSAB, TNFR1 antagonistic antibody; EHD2-scTNFR2, TNFR2 agonist; CD8+ T cell, cytotoxic T cells; CD4+ T cells, helper T cells; DC, dendritic cell; BBB, blood–brain barrier; Tregs, regulatory T cells; CNS, central nervous system; OPCs, oligodendrocyte’s precursor cells; OLGs, oligodendrocytes; TNFα, tumor necrosis factor alpha.

References

    1. Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to immune privileged sites: absolute barriers versus educational gates. Nat Rev Immunol (2013) 13:206–18.10.1038/nri3391
    1. Hellings N, Barée M, Verhoeven C, D’hooghe MB, Medaer R, Bernard CC, et al. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J Neurosci Res (2001) 63:290–302.10.1002/1097-4547(20010201)63:3<290::AID-JNR1023>;2-4
    1. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol (2015) 15(9):545–58.10.1038/nri3871
    1. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci (2012) 13(7):507–14.10.1038/nrn3275
    1. Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med (2014) 20(3):179–87.10.1016/j.molmed.2013.11.007
    1. LeVine SM. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses (1992) 39(3):271–4.10.1016/0306-9877(92)90121-R
    1. David MA, Tayebi M. Detection of protein aggregates in brain and cerebrospinal fluid derived from multiple sclerosis patients. Front Neurol (2014) 5:251.10.3389/fneur.2014.00251
    1. Macchi B, Marino-Merlo F, Nocentini U, Pisani V, Cuzzocrea S, Grelli S, et al. Role of inflammation and apoptosis in multiple sclerosis: comparative analysis between the periphery and the central nervous system. J Neuroimmunol (2015) 287:80–7.10.1016/j.jneuroim.2015.08.016
    1. Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol (2014) 10(4):225–38.10.1038/nrneurol.2014.37
    1. Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett (2011) 585(23):3715–23.10.1016/j.febslet.2011.08.004
    1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc (2014) 89(2):225–40.10.1016/j.mayocp.2013.11.002
    1. Burnet FM, Medawar P. Nobel Lectures, Physiology of Medicine 1942-1962. Amsterdam: Elsevier; (1964).
    1. Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis (2015) 3-4:151–5.10.12691/ijcd-3-4-8
    1. Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors – state of knowledge. Arch Med Sci (2014) 10(6):1175–85.10.5114/aoms.2014.47827
    1. Silva-Fernandez L, Hyrich K. Rheumatoid arthritis: when TNF inhibitors fail in RA—weighing up the options. Nat Rev Rheumatol (2014) 10:262–4.10.1038/nrrheum.2014.34
    1. Roda G, Jharap B, Neeraj N, Colombel J-F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol (2016) 7(1):e135.10.1038/ctg.2015.63
    1. Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, et al. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol (2013) 169:666–72.10.1111/bjd.12422
    1. Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int (2011) 31(3):327–37.10.1007/s00296-009-1292-x
    1. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol (2002) 20(6 Suppl 28):S152–7.
    1. The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology (1999) 53:457–65.10.1212/WNL.53.3.457
    1. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J. Neuropathology resembling CIDP in patients receiving tumour necrosis factor-a blockers. Neurology (2005) 64:1468–70.10.1212/01.WNL.0000158681.29117.8B
    1. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology (2001) 57:1885–8.10.1212/WNL.57.10.1885
    1. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum (2001) 44:1977–83.10.1002/1529-0131(200109)44:9<1977::AID-ART345>;2-6
    1. Van Herreweghe F, Festjens N, Declercq W, Vandenabeele P. Tumor necrosis factor-mediated cell death: to break or to burst, that’s the question. Cell Mol Life Sci (2010) 67:1567–79.10.1007/s00018-010-0283-0
    1. Martinez TN, Chen X, Bandyopadhyay S, Merrill AH, Tansey MG. Ceramide sphingolipid signaling mediates tumor necrosis factor (TNF)-dependent toxicity via caspase signaling in dopaminergic neurons. Mol Neurodegener (2012) 7:45.10.1186/1750-1326-7-45
    1. Probert L, Eugster HP, Akassoglou K, Bauer J, Frei K, Lassmann H, et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease. Brain (2000) 123(10):2005–19.10.1093/brain/123.10.2005
    1. Smyth MJ, Johnstone RW. Role of TNF in lymphocyte-mediated cytotoxicity. Microsc Res Tech (2000) 50:196–208.10.1002/1097-0029(20000801)50:3<196::AID-JEMT3>;2-9
    1. Kim EY, Priatel JJ, Teh SJ, Teh HS. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol (2006) 176:1026–35.10.4049/jimmunol.176.2.1026
    1. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov (2010) 9:482–93.10.1038/nrd3030
    1. Probert L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience (2015) 302:2–22.10.1016/j.neuroscience.2015.06.038
    1. Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol (2013) 230(3):241–8.10.1002/path.4188
    1. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ (2003) 10(1):45–65.10.1038/sj.cdd.4401189
    1. Naudé PJW, den Boer JA, Luiten PGM, Eisel ULM. Tumor necrosis factor receptor cross-talk. FEBS J (2011) 278:888–98.10.1111/j.1742-4658.2011.08017.x
    1. Dong Y, Dekens DW, De Deyn PP, Naudé PJW, Eisel ULM. Targeting of tumor necrosis factor alpha receptors as a therapeutic strategy for neurodegenerative disorders. Antibodies (2015) 4:369–408.10.3390/antib4040369
    1. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell (2003) 114:181–90.10.1016/S0092-8674(03)00521-X
    1. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci (2002) 216:1–7.10.1523/JNEUROSCI.22-07-j0001.2002
    1. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel U. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-d-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem (2004) 279:32869–81.10.1074/jbc.M311766200
    1. Eisel ULM, Biber K, Luiten PGM. Life and death of nerve cells: therapeutic cytokine signaling pathways. Curr Signal Transduct Ther (2006) 1:133–46.10.2174/157436206777012057
    1. Wajant H, Scheurich P. TNFR1-induced activation of the classical NF-κB pathway. FEBS J (2011) 278(6):862–76.10.1111/j.1742-4658.2011.08015.x
    1. O’Donnell MA, Ting AT. RIP1 comes back to life as a cell death regulator in TNFR1 signaling. FEBS J (2011) 278:877–87.10.1111/j.1742-4658.2011.08016.x
    1. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 281:1680–3.10.1126/science.281.5383.1680
    1. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell (2006) 22:245–57.10.1016/j.molcel.2006.03.026
    1. Juo P, Kuo CJ, Yuan J, Blenis J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol (1998) 8:1001–8.10.1016/S0960-9822(07)00420-4
    1. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol (2001) 21:5299–305.10.1128/MCB.21.16.5299-5305.2001
    1. Bigda J, Beletsky I, Brakebusch C, Varfolomeev Y, Engelmann H, Bigda J, et al. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med (1994) 180:445–60.10.1084/jem.180.2.445
    1. Fotin-Mleczek M, Henkler F, Samel D, Reichwein M, Hausser A, Parmryd I, et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci (2002) 115:2757–70.
    1. Wicovsky A, Henkler F, Salzmann S, Scheurich P, Kneitz C, Wajant H. Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1–TNFR2 cooperation. Oncogene (2009) 28:1769–81.10.1038/onc.2009.219
    1. Richter C, Messerschmidt S, Holeiter G, Tepperink J, Osswald S, Zappe A, et al. The tumor necrosis factor receptor stalk regions define responsiveness to soluble versus membrane-bound ligand. Mol Cell Biol (2012) 32:2515–29.10.1128/MCB.06458-11
    1. Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 164(4):1079–106.10.1111/j.1476-5381.2011.01302.x
    1. Zendedel A, Beyer C, Kipp M. Cuprizone-induced demyelination as a tool to study remyelination and axonal protection. J Mol Neurosci (2013) 51(2):567–72.10.1007/s12031-013-0026-4
    1. Luiten PG, Douma BR, Van der Zee EA, Nyakas C. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration (1995) 4(3):307–14.10.1016/1055-8330(95)90020-9
    1. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I.The relevance of animal models in multiple sclerosis research. Pathophysiology (2011) 18(1):21–9.10.1016/j.pathophys.2010.04.004
    1. Ransohoff RM. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci (2012) 15(8):1074–7.10.1038/nn.3168
    1. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov (2004) 3(5):401–16.10.1038/nrd1383
    1. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol (2005) 6(12):1191–7.10.1038/ni1276
    1. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol (2013) 13(1):59–66.10.1038/nri3362
    1. Chen X, Bäumel M, Männel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol (2007) 179(1):154–61.10.4049/jimmunol.179.1.154
    1. Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J Exp Med (2016) 213(7):1241–53.10.1084/jem.20151255
    1. Miller PG, Bonn MB, McKarns SC. Transmembrane TNF-TNFR2 impairs Th17 differentiation by promoting Il2 expression. J Immunol (2015) 195(6):2633–47.10.4049/jimmunol.1500286
    1. Williams SK, Maier O, Fischer R, Fairless R, Hochmeister S, Stojic A, et al. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS One (2014) 9(2):e90117.10.1371/journal.pone.0090117
    1. Veroni C, Gabriele L, Canini I, Castiello L, Coccia E, Remoli ME, et al. Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Mol Cell Neurosci (2010) 45(3):234–44.10.1016/j.mcn.2010.06.014
    1. Gao H, Danzi MC, Choi CS, Taherian M, Dalby-Hansen C, Ellman DG, et al. Opposing functions of microglial and macrophagic TNFR2 in the pathogenesis of experimental autoimmune encephalomyelitis. Cell Rep (2017) 18(1):198–212.10.1016/j.celrep.2016.11.083
    1. Maier O, Fischer R, Agresti C, Pfizenmaier K. TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. Biochem Biophys Res Commun (2013) 440(2):336–41.10.1016/j.bbrc.2013.09.083
    1. Blakemore WF, Keirstead HS. The origin of remyelinating cells in the central nervous system. J Neuroimmunol (1999) 98:69–76.10.1016/S0165-5728(99)00083-1
    1. Fischer R, Wajant H, Kontermann R, Pfizenmaier K, Maier O. Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia (2014) 62:272–83.10.1002/glia.22605
    1. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination.Nat Neurosci (2001) 4:1116–22.10.1038/nn738
    1. Brambilla R, Ashbaugh JJ, Magliozzi R, Dellarole A, Karmally S, Szymkowski DE, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain (2011) 134:2736–54.10.1093/brain/awr199
    1. Madsen PM, Motti D, Karmally S, Szymkowski DE, Lambertsen KL, Bethea JR, et al. Oligodendroglial TNFR2 mediates membrane TNF-dependent repair in experimental autoimmune encephalomyelitis by promoting oligodendrocyte differentiation and remyelination. J Neurosci (2016) 36(18):5128–43.10.1523/JNEUROSCI.0211-16.2016
    1. Karamita M, Barnum C, Möbius W, Tansey MG, Szymkowski DE, Lassmann H, et al. Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. JCI Insight (2017) 2(8):e87455.10.1172/jci.insight.87455
    1. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol (2012) 8(11):647–56.10.1038/nrneurol.2012.168
    1. Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier K. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One (2011) 6:e27621.10.1371/journal.pone.0027621
    1. Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis (2008) 13(2):111–22.10.3233/JAD-2008-13201
    1. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet (2014) 383(9936):2213–21.10.1016/S0140-6736(13)62242-4
    1. Madsen PM, Clausen BH, Degn M, Thyssen S, Kristensen LK, Svensson M, et al. Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia. J Cereb Blood Flow Metab (2016) 36(9):1553–69.10.1177/0271678X15610339
    1. Dong Y, Fischer R, Naudé PJ, Maier O, Nyakas C, Duffey M, et al. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proc Natl Acad Sci U S A (2016) 113(43):12304–9.10.1073/pnas.1605195113
    1. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science (2012) 335(6071):936–41.10.1126/science.1214935
    1. Read AF, Graham AL, Råberg L. Animal defenses against infectious agents: is damage control more important than pathogen control? PLoS Biol (2008) 6(12):10.10.1371/journal.pbio.1000004
    1. Ayres JS, Schneider DS. Two ways to survive an infection: what resistance and tolerance can teach us about treatments for infectious diseases. Nat Rev Immunol (2008) 8(11):889–95.10.1038/nri2432
    1. Ayres JS, Freitag N, Schneider DS. Identification of Drosophila mutants altering defense of and endurance to Listeria monocytogenes infection. Genetics (2008) 178:1807–15.10.1534/genetics.107.083782
    1. Seixas E, Gozzelino R, Chora A, Ferreira A, Silva G, Larsen R, et al. Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Proc Natl Acad Sci U S A (2009) 106:15837–42.10.1073/pnas.0903419106
    1. Gozzelino R, Andrade BB, Larsen R, Luz NF, Vanoaica L, Seixas E, et al. Metabolic adaptation to tissue iron overload confers tolerance to malaria.Cell Host Microbe (2012) 12:693–704.10.1016/j.chom.2012.10.011
    1. Soares MP, Teixeira L, Moita LF. Disease tolerance and immunity in host protection against infection. Nat Rev Immunol (2017) 17(2):83–96.10.1038/nri.2016.136
    1. Gao W, Zhang L. Coating nanoparticles with cell membranes for targeted drug delivery. J Drug Target (2015) 23(7–8):619–26.10.3109/1061186X.2015.1052074
    1. Singh R, Lillard JW, Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol (2009) 86(3):215–23.10.1016/j.yexmp.2008.12.004
    1. Frenz T, Grabski E, Durán V, Hozsa C, Stępczyńska A, Furch M, et al. Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers. Eur J Pharm Biopharm (2015) 95(Pt A):13–7.10.1016/j.ejpb.2015.02.008
    1. Biber K, Möller T, Boddeke E, Prinz M. Central nervous system myeloid cells as drug targets: current status and translational challenges. Nat Rev Drug Discov (2016) 15(2):110–24.10.1038/nrd.2015.14

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi